Shane Cooke Sells 1,900 Shares of Alkermes Plc (ALKS) Stock

Alkermes Plc (NASDAQ:ALKS) insider Shane Cooke sold 1,900 shares of Alkermes Plc stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $60.09, for a total transaction of $114,171.00. Following the sale, the insider now owns 72,048 shares of the company’s stock, valued at $4,329,364.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shane Cooke also recently made the following trade(s):

  • On Wednesday, March 29th, Shane Cooke sold 2,070 shares of Alkermes Plc stock. The shares were sold at an average price of $60.00, for a total transaction of $124,200.00.
  • On Thursday, March 23rd, Shane Cooke sold 6,030 shares of Alkermes Plc stock. The shares were sold at an average price of $60.01, for a total transaction of $361,860.30.
  • On Monday, March 20th, Shane Cooke sold 300 shares of Alkermes Plc stock. The stock was sold at an average price of $60.00, for a total transaction of $18,000.00.
  • On Thursday, March 2nd, Shane Cooke sold 20,000 shares of Alkermes Plc stock. The stock was sold at an average price of $60.00, for a total transaction of $1,200,000.00.
  • On Monday, January 9th, Shane Cooke sold 550 shares of Alkermes Plc stock. The stock was sold at an average price of $60.27, for a total transaction of $33,148.50.
  • On Friday, January 6th, Shane Cooke sold 9,450 shares of Alkermes Plc stock. The stock was sold at an average price of $60.06, for a total transaction of $567,567.00.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 0.50% during trading on Thursday, hitting $56.73. 429,555 shares of the stock were exchanged. Alkermes Plc has a 12-month low of $36.71 and a 12-month high of $62.50. The firm has a 50 day moving average of $58.15 and a 200-day moving average of $55.28. The company’s market cap is $8.65 billion.

Alkermes Plc (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 15th. The company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.11. The firm had revenue of $213.50 million for the quarter, compared to the consensus estimate of $206.38 million. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The business’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.14) EPS. On average, analysts forecast that Alkermes Plc will post $0.04 earnings per share for the current year.

Insider Buying and Selling by Quarter for Alkermes Plc (NASDAQ:ALKS)

TRADEMARK VIOLATION NOTICE: “Shane Cooke Sells 1,900 Shares of Alkermes Plc (ALKS) Stock” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/20/shane-cooke-sells-1900-shares-of-alkermes-plc-alks-stock-updated-updated.html.

A number of research firms have weighed in on ALKS. Cowen and Company reissued a “positive” rating and set a $65.00 price objective on shares of Alkermes Plc in a report on Tuesday, March 21st. Jefferies Group LLC reissued a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a report on Monday, April 3rd. Cantor Fitzgerald reissued a “neutral” rating and set a $51.00 price objective on shares of Alkermes Plc in a report on Thursday, March 16th. Finally, TheStreet raised shares of Alkermes Plc from a “d+” rating to a “c” rating in a report on Wednesday, February 15th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Alkermes Plc presently has a consensus rating of “Buy” and an average price target of $63.55.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Massey Quick & Co. LLC bought a new position in shares of Alkermes Plc during the fourth quarter valued at approximately $111,000. Hall Laurie J Trustee bought a new position in shares of Alkermes Plc during the fourth quarter valued at approximately $154,000. Daiwa Securities Group Inc. increased its position in shares of Alkermes Plc by 11.8% in the third quarter. Daiwa Securities Group Inc. now owns 3,800 shares of the company’s stock valued at $179,000 after buying an additional 400 shares during the last quarter. TLP Group LLC bought a new position in shares of Alkermes Plc during the third quarter valued at approximately $187,000. Finally, Greenwood Capital Associates LLC bought a new position in shares of Alkermes Plc during the fourth quarter valued at approximately $202,000. 95.52% of the stock is currently owned by hedge funds and other institutional investors.

About Alkermes Plc

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

5 Day Chart for NASDAQ:ALKS

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply